New Targeted Therapies for Chronic Myelogenous Leukemia: Opportunities to Overcome Imatinib Resistance

Seminars in Hematology

Volumn 44, Issue SUPPL. 1, 2007, Pages 25-31

  Jabbour, Elias ^a   Cortes, Jorge ^a   O'Brien, Susan ^a   Giles, Francis ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 5 AZA 2' DEOXYCYTIDINE; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AT 9283; BCR ABL PROTEIN; BOSUTINIB; CANCER VACCINE; CGP 76030; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; HOMOHARRINGTONINE; IMATINIB; INNO 406; KW 2449; LONAFARNIB; NILOTINIB; NS 187; ON 012380; ON 01910; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TIPIFARNIB; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER PATIENT; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; IMMUNOMODULATION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MUSCLE SPASM; NEUTROPENIA; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANILINE COMPOUNDS; CANCER VACCINES; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; NITRILES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; QUINOLINES; THIAZOLES;

EID: 33846849302     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2006.12.003     Document Type: Article

References (60)

1. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., and Kantarjian H.M. The biology of chronic myeloid leukemia. N Engl J Med 341 (1999) 164-172
2. Goldman J.M., and Melo J.V. Chronic myeloid leukemia-Advances in biology and new approaches to treatment. N Engl J Med 349 (2003) 1451-1464
3. Kantarjian H.M., Cortes J.E., O'Brien S., et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α. Blood 104 (2004) 1979-1988
4. Kantarjian H., Sawyers C., Hochhaus A., et al., International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346 (2002) 645-652
5. O'Brien S.G., Guilhot F., Larson R.A., et al., IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (2003) 994-1004
6. Kantarjian H., Talpaz M., O'Brien S., et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103 (2004) 2873-2878
7. Cortes J., Talpaz M., O'Brien S., et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 11 (2005) 3425-3432
8. Hughes T.P., Kaeda J., Branford S., et al., International Randomised Study of Interferon versus STI571 Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349 (2003) 1423-1432
9. Shah N.P. Loss of response to imatinib: Mechanisms and management. Hematol Am Soc Hematol Educ Program (2005) 183-187
10. Hochhaus A., Kreil S., Corbin A.S., et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16 (2002) 2190-2196
11. Manley P.W., Cowan-Jacob S.W., and Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta 1754 (2005) 3-13
12. Gambacorti-Passerini C.B., Gunby R.H., Piazza R., Galietta A., Rostagno R., and Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 4 (2003) 75-85
13. Gorre M.E., Mohammed M., Ellwood K., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880
14. Branford S., Rudzki Z., Walsh S., et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102 (2003) 276-283
15. Gambacorti-Passerini C., Zucchetti M., Russo D., et al. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 9 (2003) 625-632
16. Donato N.J., Wu J.Y., Stapley J., et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 64 (2004) 672-677
17. Donato N.J., Wu J.Y., Stapley J., et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101 (2003) 690-698
18. Branford S., Rudzki Z., Walsh S., et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99 (2002) 3472-3475
19. Soverini S., Martinelli G., Rosti G., et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 23 (2005) 4100-4109
20. Jabbour E., Kantarjian H., Jones D., et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20 (2006) 1767-1773
21. O'Hare T., Walters D.K., Stoffregen E.P., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65 (2005) 4500-4505
22. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., and Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
23. Tokarski J.S., Newitt J.A., Chang C.Y., et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66 (2006) 5790-5797
24. Talpaz M., Shah N.P., Kantarjian H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354 (2006) 2531-2541
25. Baccarani M., Kantarjian H.M., Apperley J.F., et al. Efficacy of dasatinib (SPRYCEL) in patients (pts) with chronic phase chronic myelogenous leukemia (CP-CML) resistant or intolerant of imatinib: Updated results of the CA180013 'START-C' phase II study. Blood 108 (2006) (abstr 164)
26. Cortes J., Kim D.W., Guilhot F., et al. Dasatinib (SPRYCEL) in patients (pts) with chronic myelogenous leukemia in accelerated phase (AP-CML) that is imatinib-resistant (im-r) or -intolerant (im-i): Updated results of the CA180-005 'START-A' phase II study. Blood 108 (2006) (abstr 2160)
27. Martinelli G., Hochhaus A., Coutre S., et al. Dasatinib (SPRYCEL) efficacy and safety in patients (pts) with chronic myelogenous leukemia in lymphoid (CML-LB) or myeloid blast (CML-MB) phase who are imatinib-resistant (im-r) or -intolerant (im-i). Blood 108 (2006) (abstr 745)
28. Dombret H., Ottmann O.G., Rosti G., et al. Dasatinib (SPRYCEL) in patients (pts) with Philadelphia chromosome-positive acute lymphoblastic leukemia who are imatinib-resistant (im-r) or -intolerant (im-i): Updated results from the CA180-015 'START-L' study. Blood 108 (2006) (abstr 286)
29. Shah N., Pasquini R., Rousselot P., et al. Dasatinib (SPRYCEL) vs escalated dose of imatinib (im) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib: Results of the CA180-017 START-R randomized study. Blood 108 (2006) (abstr 167)
30. Sprycel (2006), Bristol-Myers Squibb Company, Princeton, NJ [package insert].
31. Weisberg E., Manley P.W., Breitenstein W., et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7 (2005) 129-141
32. Verstovsek S., Golemovic M., Kantarjian H., et al. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 104 (2005) 1230-1236
33. Weisberg E., Manley P., Mestan J., Cowan-Jacob S., Ray A., and Griffin J.D. AMN107 (nilotinib): A novel and selective inhibitor Bcr-Abl. Br J Cancer 7 (2006) 129-141
34. Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354 (2006) 2542-2551
35. Le Coutre P., Bhalla K., Giles F., et al. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant and -intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP). Blood 108 (2006) (abstr 165)
36. Kantarjian H.M., Gattermann N., Hochhaus A., et al. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant or -intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP). Blood 108 (2006) (abstr 2169)
37. Giles F.J., Larson R., Le Coutre P., et al. A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with Ph+ chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL). Proc Am Soc Clin Oncol 24 (2006) (abstr 6536)
38. Jabbour E., Giles F., Cortes J., et al. Preliminary activity of AMN107, a novel potent oral selective Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP). Proc Am Soc Clin Oncol 24 (2006) (abstr 6591)
39. Golas J.M., Arndt K., Etienne C., et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 63 (2003) 375-381
40. Kimura S., Naito H., Segawa H., et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 106 (2005) 3948-3954
41. O'Hare T., Pollock R., Stoffregen E.P., et al. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood 104 (2004) 2532-2539
42. Warmuth M., Simon N., Mitina O., et al. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood 101 (2003) 664-672
43. Gumireddy K., Baker S.J., Cosenza S.C., et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci U S A 102 (2005) 1992-1997
44. Gumireddy K., Reddy M.V., Cosenza S.C., et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7 (2005) 275-286
45. Carter T.A., Wodicka L.M., Shah N.P., et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A 102 (2005) 11011-11016
46. Barrett J. Allogeneic stem cell transplantation for chronic myeloid leukemia. Semin Hematol 40 (2003) 59-71
47. Guilhot F., and Lacotte-Thierry L. Interferon-alpha: mechanisms of action in chronic myelogenous leukemia in chronic phase. Hematol Cell Ther 40 (1998) 237-239
48. Pinilla-Ibarz J., Cathcart K., Korontsvit T., et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 95 (2000) 1781-1787
49. Cathcart K., Pinilla-Ibarz J., Korontsvit T., et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 103 (2004) 1037-1042
50. Bocchia M., Gentili S., Abruzzese E., et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: A multicentre observational trial. Lancet 365 (2005) 657-662
51. Qazilbash M.H., Weider E., Rios R., et al. Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia. Blood 104 (2004) 77a (abstr 259)
52. Li Z., Qiao Y., Laska E., et al. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein 70 vaccine for chronic myelogenous leukemia. Proc Am Soc Clin Oncol 22 (2003) 166 (abstr 664)
53. Cortes J., Albitar M., Thomas D., et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 101 (2003) 1692-1697
54. Borthakur G., Kantarjian H., Daley G., et al. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer 106 (2006) 346-352
55. Cortes J., Garcia-Manero G., O'Brien S., et al. A phase I study of tipifarnib in combination with imatinib mesylate for patients with chronic myeloid leukemia in chronic phase who failed imatinib therapy. Blood 104 (2004) 289a (abstr1011)
56. Cortes J., O'Brien S., Verstovsek S., et al. Phase I study of lonafarnib in combination with imatinib mesylate for patients with chronic myeloid leukemia after failure to imatinib. Blood 104 (2004) 288a (abstr 1009)
57. Issa J.P., Gharibyan V., Cortes J., et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23 (2005) 3948-3956
58. Quintas-Cardama A., Cortes J., Verstovsek S., Laddie N., Estrov Z., and Kantarjian H. Subcutaneous (SC) homoharringtonine (HHT) for patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP) after imatinib mesylate failure. Blood 106 (2005) (abstr 4839)
59. Jabbour E., Cortes J., Kantarjian H.M., et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 108 (2006) 1421-1423
60. De Lima M., Jabbour E., Cortes J., et al. Novel tyrosine kinase inhibitor therapy (NTKI) prior to allogeneic stem cell transplantation (ASCT) in patients (pts) with chronic myeloid leukemia: No evidence for increased transplant-related toxicity. Proc Am Soc Clin Oncol 24 (2006) (abstr 16515)